MET and breast carcinoma: The OC effects on MDA-MB-231, MCF-7 and BT-474 breast cancer cells were mediated by the inhibition of HGF-induced c-Met activation and its downstream mitogenic signaling pathways, thus decreasing proliferation and cell survival [156].